The concordant risk effects observed across both eQTL and pQTL analyses (P < 0.05), coupled with the absence of genome-wide pleiotropy in PheWAS (P < 5 × 10−8), underscore CPXM1 as a prioritized therapeutic target for osteoporosis. The gene discussed is CPXM1; the disease is osteoporosis.